From the laboratory to the clinic: A retrospective on fully synthetic carbohydrate-based anticancer vaccines

Angewandte Chemie (International Edition in English)

Volumn 39, Issue 5, 2000, Pages

  Danishefsky, Samuel J ^a,b   Allen, Jennifer R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Havemeyer Hall ^*  (United States)

Author keywords

Carbohydrates; Drug research; Glycoconjugates; Tumor therapy; Vaccines

Indexed keywords

CANCER VACCINE; CARBOHYDRATE DERIVATIVE; GLYCOCONJUGATE;

ANTIBODY PRODUCTION; CANCER THERAPY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOSTIMULATION; METASTASIS; NONHUMAN; REVIEW; TUMOR CELL; VACCINATION;

EID: 0034599121     PISSN: 05700833     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-3773(20000303)39:5<836::aid-anie836>3.0.co;2-i     Document Type: Review

References (187)

1. A. M. Silverstein in A History of Immunology, Academic Press, San Diego, 1989, chap. 1 and 12.
2. a) Lanzavecchia, Science 1993, 260, 937-944;
3. b) D. M. Pardoll, Curr. Opin. Immunol. 1993, 5, 719-725;
4. c) P. O. Livingston, Curr. Opin. Immunol. 1992, 4, 2;
5. d) G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, R. C. Mulligan, Proc. Natl. Acad. Sci. USA 1993, 90, 3539;
6. e) M.-H. Tao, R. Levy, Nature 1993, 362, 755;
7. f) T. Boon, Int. J. Cancer, 1993, 54, 177.
8. a) S. Hakomori, Cancer Res. 1985, 45, 2405;
9. b) T. Feizi, Cancer Surv. 1985, 4, 245;
10. c) K. O. Lloyd, Cancer Biol. 1991, 2, 421;
11. d) P. O. Livingston, Immunol. Rev. 1995, 145, 147-166;
12. e) Y. J. Kim, A. Varki, Glycoconjugate J. 1997, 14, 569.
13. a) S. Ho, Y. S. Kim, Semin. Cancer Biol. 1991, 2, 389;
14. b) A. K. Singal, Semin. Cancer Biol. 1991, 2, 379;
15. c) S. R. Hull, A. Bright, K. L. Carraway, Cancer Commun. 1989, 1, 261;
16. d) S. Hakomori, Cancer Cells 1991, 3, 461;
17. e) S. Hakomori, Cancer Res. 1996, 56, 5309.
18. For a review, see: S. Hakomori, Y. Zhang, Chem. Biol. 1997, 4, 97.
19. For some early successes, see: a) G. D. MacLean, M. B. Bowen-Yacyshyn, J. Samuel, A. Meikle, G. Stuart, J. Nation, S. Poppema, M. Jerry, R. Koganty, T. Wong, B. M. Longnecker, J. Immunol. 1992, 11, 292;
20. b) P. Y. S. Fung, M. Made, R. R. Koganty, B. M. Longnecker, Cancer Res. 1990, 50, 4308;
21. c) P. O. Livingston, G. Ritter, P. Srivastava, M. Padavan, M. J. Calves, H. F. Oettgen, L. J. Old, Cancer Res. 1989, 49, 7045;
22. d) Y. Haraday, M. Sakatsume, G. A. Nores, S. Hakomori, M. Taniguchi, Jpn. J. Cancer Res. 1989, 80, 988.
23. a) P. O. Livingston, S. Zhang, K. O. Lloyd, Cancer Immunol. Immunother. 1997, 45, 1;
24. b) G. Ragupathi, Cancer Immunol. Immunother. 1996, 43, 152.
25. a) I. Hellstrom, K. E. Hellstrom, J. Immunother. 1998, 21, 119;
26. b) P. Möller, G. Hammerling, Cancer Surv. 1992, 13, 101.
27. a) A. J. Treves, C. Carnaud, N. Tranin, M. Feldman, I. R. Cohen, Eur. J. Immunol. 1974, 4, 722;
28. b) S. Fujimoto, M. I. Greene, A. H. Sehon, J. Immunol. 1976, 116, 791;
29. c) D. Naor, Adv. Cancer Res. 1979, 29, 45;
30. d) E. S. Dye, R. J. North, J. Exp. Med. 1981, 154, 1033;
31. d) H. Kirchner, T. M. Chused, R. B. Herberman, H. T. Holden, D. H. Lavrin, J. Exp. Med. 1974, 139, 1473.
32. a) T. Fujii, T. Igarashi, S. Kishimoto, J. Natl. Cancer Inst. 1987, 78, 509;
33. b) I. Kamo, H. Freidman, Adv. Cancer Res. 1977, 25, 271;
34. c) K. E. Hellstrom, I. Hellstrom, Adv. Immunol. 1974, 18, 209;
35. d) J. Tamerius, J. Nepom, I. Hellstrom, K. E. Hellstrom, J. Immunol. 1976, 116, 724;
36. e) T. Tada, S. Ohzeki, K. Utsumi, H. Takiuchi, M. Muramatsu, X-F. Li, J. Shimizu, H. Fujiwara, T. Hamaoka, J. Immunol. 1991, 146, 1077.
37. a) W. F. Bodmer, M. J. Browning, P. Krausa, A. Rowan, D. C. Bicknell, Ann. N. Y. Acad. Sci. 1993, 690, 42;
38. b) H. Ikeda, B. Lethe, F. Lehmann, N. van Baren, J. F. Baurain, C. de-Smet, H. Chambost, M. Vitale, A. Moretta, T. Boon, P. G. Coulie, Immunity 1997, 6, 199;
39. c) G. Torre Amione, R. D. Beauchamp, H. Koeppen, B. H. Park, H. Schreiber, H. L. Moses, D. A. Rowley, Proc. Natl. Acad. Sci. USA 1990, 87, 1486.
40. a) P. O. Livingston, Immunol. Rev. 1995, 145, 147;
41. b) L. J. Old, Cancer Res. 1981, 41, 361.
42. P. O. Livingston in Molecular Diagnosis, Prevention and Treatment of Melanoma (Ed.: J. K. Kirkwood), New York, 1997.
43. a) P. C. Jones, L. L. Sze, P. Y. Lui, D. L. Morton, R. F. Irie, J. Natl. Cancer Inst. 1981, 66, 249;
44. b) P. O. Livingston, G. Y. Wong, S. Adulri, Y. Tao, M. Padavan, R. Parente, C. Hanlon, M. J. Calves, F. Helling, G. Ritter, J. Clin. Oncol. 1994, 12, 1036;
45. c) S. F. Winter, Y. Sekido, J. D. Minna, D. McIntire, B. E. Johnson, A. F. Gazdar, D. P. Carbone, J. Natl. Cancer Inst. 1993, 85, 2012;
46. d) G. Reithmüller, E. Schneider-Gadicke, G. Schlimok, W. Schmiegel, R. Raab, K. Höffken, R. Gruber, H. Pichlmaier, H. Hirche, R. Pichlmayr, P. Buggisch, J. Witte, and the German Cancer Aid 17-IA Study Group, Lancet 1994, 343, 1177.
47. a) J. Portoukalian, S. Carrel, J. F. Dore, P. Rumke, Int. J. Cancer 1991, 49, 893;
48. b) M. H. Ravindranath, D. L. Morton, R. F. Irie, Cancer Res. 1989, 49, 3891.
49. M. J. Francis in Vaccines: Recent Trends and Progress (Eds.: G. Gregoriadis, A. C. Allison, G. Poste), Plenum Press, New York, 1991.
50. a) T. Feizi, Curr. Opin. Struct. Biol. 1993, 3, 701;
51. b) S. D. Rosen, C. R. Bertozzi, Curr. Biol. 1996, 6, 261;
52. c) A. Varki, Glycobiology 1993, 3, 97;
53. d) M. L. Phillips, E. Nudelman, F. C. A. Gaeta, M. Perez, A. K. Singal, S. Hakomori, J. C. Paulson, Science 1990, 250, 1130;
54. e) M. J. Polley, M. L. Phillips, E. Wagner, E. Nudelman, A. K. Singal, S. Hakomori, J. C. Paulson, Proc. Natl. Acad. Sci. USA 1991, 88, 6224;
55. f) L. A. Lasky, Science 1992, 258, 964;
56. g) D. J. Miller, M. B. Macek, B. D. Schur, Nature 1992, 357, 589;
57. h) T. Feizi, Nature 1985, 314, 53.
58. J. B. Lowe in The Molecular Basis of Blood Diseases (Eds.: G. Stamatoyannopolous, A. W. Nienhuis, P. W. Majerus, H. Varmus), Saunders, Philadelphia, 1987, chap. 8.
59. a) G. D. MacLean, M. A. Reddish, M. B. Bowen-Yacyshyn, S. Poppema, B. M. Longnecker, Cancer Investigat. 1994, 12, 46;
60. b) T. Toyokuni, A. K. Singhal, Chem. Soc. Rev. 1995, 24, 23;
61. c) R. Lo-Man, S. Bay, S. Vicher-Guerre, E. Deriaud, D. Cantacuzene, C. Leclerc, Cancer Res. 1999, 59, 1520, and references therein.
62. a) S. J. Danishefsky, M. T. Bilodeau, Angew. Chem. 1996, 108, 1482;
63. Angew. Chem. Int. Ed. Engl. 1996, 35, 1380.
64. a) M. R. Stroud, S. B. Levery, S. Martensson, M. E. K. Salyan, H. Clausen, S. Hakomori, Biochemistry 1994, 33, 10672;
65. b) C.-T. Yuen, K. Bezouska, J. O'Brien, M. Stoll, R. Lemoine, A. Lubineau, M. Kiso, A. Hasegawa, N. J. Bockovich, K. C. Nicolaou, T. Feizi, J. Biochem. 1994, 269, 1595;
66. c) M. R. Stroud, S. B. Levery, E. Nudelman, M. E. K. Salyan, J. A. Towell, C. E. Roberts, M. Watanabe, S. Hakomori, J. Biol. Chem. 1991, 266, 8439.
67. a) M. A. Bernstein, L. D. Hall, Carbohydr. Res. 1980, 78, C1;
68. b) R. U. Lemieux, Chem. Soc. Rev. 1978, 7, 423, and references therein.
69. S. Müller, S. Goletz, N. Packer, A. Gooley, A. M. Lawson, F.-G. Hanisch, J. Biol. Chem. 1997, 272, 24780.
70. S. J. Danishefsky, V. Behar, J. T. Randolph, K. O. Lloyd, J. Am. Chem. Soc. 1995, 117, 5701.
71. a) K. O. Lloyd, Am. J. Clin. Pathol. 1987, 87, 129;
72. b) K. O. Lloyd, Cancer Biol. 1991, 2, 421.
73. B. W. Yin, C. L. Finstad, K. Kitamura, M. G. Federici, M. Welshinger, V. Kudryashov, W. J. Hoskins, S. Welt, K. O. Lloyd, Int. J. Cancer 1996, 65, 406.
74. W. N. Haworth, E. L. Hirst, M. M. T. Plant, R. J. W. Reynolds, J. Chem. Soc. 1930, 2644.
75. T. Mukaiyama, Y. Murai, S. Shoda, Chem. Lett. 1981, 431.
76. S. J. Danishefsky, J. Gervay, J. M. Peterson, F. E. McDonald, K. Koseki, T. Oriyama, D. A. Griffith, C.-H. Wong, D. P. Dumas, J. Am. Chem. Soc. 1992, 114, 8329.
77. a) S. J. Danishefsky, K. Koseki, D. A. Griffith, J. Gervay, J. M. Peterson, F. E. McDonald, T. Oriyama, J. Am. Chem. Soc. 1992, 114, 8331;
78. b) D. A. Griffith, S. J. Danishefsky, J. Am. Chem. Soc. 1990, 112, 5811;
79. c) D. A. Griffith, S. J. Danishefsky, J. Am. Chem. Soc. 1991, 113, 5863.
80. R. L. Halcomb, S. J. Danishefsky, J. Am. Chem. Soc. 1989, 111, 6661.
81. For sugar anaylsis protocols, see: a) K. O. Lloyd, A. Savage, Glyconjugate J. 1991, 8, 493;
82. b) M. R. Hardy, R. R. Townsend, Proc. Natl. Acad. Sci. USA 1988, 85, 3289.
83. V. Behar, PhD thesis, Columbia University, New York, 1994.
84. R. R. Schmidt, P. Zimmermann, Tetrahedron Lett. 1986, 27, 481.
85. V. Kudryashov, H. M. Kim, G. Ragupathi, S. J. Danishefsky, P. O. Livingston, K. O. Lloyd, Cancer Immunol. Immunother. 1998, 45, 281.
86. a) In previous studies, QS-21 has been shown to be superior to other adjuvants. In addition, it is non-toxic and safe for human use: P. O. Livingston, R. R. Koganty, B. M. Longnecker, K. O. Lloyd, M. J. Calves, Vaccine Res. 1991, 1, 99;
87. b) C. R. Kensil, U. Patel, M. Lennick, D. Marciani, J. Immunol. 1991, 146, 431.
88. This conjugate was prepared by a recently devised procedure in which the carbohydrate is first coupled to 4-(N-maleidomethyl)cyclohexane-1-carboxyhydrazide (M2C2H) and the product, in turn, is coupled to 2-iminothiolane-derivatized KLH. The product yields with 15 are much-improved by using this method (39% based on sugar recovery) and the ratio of carbohydrate:protein is superior to KLH conjugates (540:1), see: G. Ragupathi, L. Howard, S. Cappello, R. R. Koganty, D. Qiu, B. M. Longnecker, M. A. Reddish, K. O. Lloyd, P. O. Livingston, Cancer Immunol. Immunother. 1999, 48, 1, and references therein.
89. Not all carbohydrate immunoconjugates are capable of eliciting antibodies. KLH conjugates appear to be particularly good at this. For a systematic comparison of carrier proteins and adjuvants see: F. Helling, Y. Shang, M. Calves, H. F. Oettgen, P. O. Livingston, Cancer Res. 1994, 54, 197.
90. a) R. Kannagi, S. B. Levery, F. Ishijamik, S. Hakomori, L. H. Schevinsky, B. B. Knowles, D. Solter, J. Biol. Chem. 1983, 258, 8934;
91. b) E. G. Bremer, S. B. Levery, S. Sonnino, R. Ghidoni, S. Canevari, R. Kannagi, S. Hakomori, J. Biol. Chem. 1984, 259, 14773.
92. S. Menard, E. Tagliahue, S. Canevari, G. Fossati, M. I. Colnaghi, Cancer Res. 1983, 43, 1295.
93. V. Kudryashov, G. Ragupathi, I. J. Kim, M. E. Breimer, S. J. Danishefsky, P. O. Livingston, K. O. Lloyd, Glycoconjugate J. 1998, 15, 243.
94. a) P. O. Livingston, Cancer Biol. 1995, 6, 357-366;
95. b) S. Zhang, C. Cordon-Cardo, H. S. Zhang, V. E. Reuter, S. Adluri, W. B. Hamilton, K. O. Lloyd, P. O. Livingston, Int. J. Cancer 1997, 3, 42-49.
96. S. Zhang, H. S. Zhang, V. E. Reuter, S. F. Slovin, H. I. Scher, P. O. Livingston, Clin. Cancer Res. 1998, 4, 295-302.
97. I. J. Kim, T. K. Park, S. Hu, K. Abrampah, S. Zhang, P. O. Livingston, S. J. Dansihefsky, J. Org. Chem. 1995, 60, 7716.
98. The syntheses of DEF and CDEF fragments of 1 have recently been reported and both structures have been shown to bind to MBr1: a) L. Lay, F. Nicotra, L. Panza, G. Russo, Helv. Chim. Acta 1994, 77, 509-514;
99. b) L. Lay, L. Panza, G. Russo, D. Colombo, F. Ronchetti, E. Adobati, S. Canevari, Helv. Chim. Acta 1995, 78, 533-538.
100. For a subsequent synthesis of the hexasaccharide moiety of Globo-H see: J. Lassaletta, R. R. Schmidt, Liebigs Ann. 1996, 1417.
101. For a preliminary communication on the total synthesis see: M. T. Bilodeau, T. K. Park, S. Hu, J. T. Randolph, S. J. Danishefsky, P. O. Livingston, S. Zhang, J. Am. Chem. Soc. 1995, 117, 7840.
102. T. K. Park, I. J. Kim, S. Hu, M. T. Bilodeau, J. T. Randolph, O. Kwon, S. J. Danishefsky, J. Am. Chem. Soc. 1996, 118, 11488.
103. a) K. C. Nicolaou, T. J. Caulifield, H. Kataoka, N. A. Stylianides, J. Am. Chem. Soc. 1990, 112, 3693;
104. b) K. C. Nicolaou, C. W. Hummel, N. J. Bockovich, C.-H. Wong, J. Chem. Soc. Chem. Commun. 1991, 870.
105. For the synthesis of SSEA-3 see: a) S. Nunomura, T. Ogawa, Tetrahedron Lett. 1988, 29, 5681;
106. b) T. K. Park, I. J. Kim, S. J. Danishefsky, Tetrahedron Lett. 1995, 36, 9089.
107. For the synthesis of Gb3 which contains the ABC trisaccharide domain see: K. C. Nicolaou, T. Caulifield, H. Kataoka, T. Kumazawa, J. Am. Chem. Soc. 1988, 110, 7910.
108. G. Ragupathi, T. K. Park, S. Zhang, I. J. Kim, L. Graber, S. Adluri, K. O. Lloyd, S. J. Danishefsky, P. O. Livingston, Angew. Chem. 1997, 109, 66; Angew. Chem. Int. Ed. Engl. 1997, 36, 125.
109. G. Ragupathi, T. K. Park, S. Zhang, I. J. Kim, L. Graber, S. Adluri, K. O. Lloyd, S. J. Danishefsky, P. O. Livingston, Angew. Chem. 1997, 109, 66; Angew. Chem. Int. Ed. Engl. 1997, 36, 125.
110. For another example of the increased immunogenicity of KLH as compared to other protein carriers see: F. Helling, S. Zhang, A. Shang, S. Adluri, M. Calves, R. R. Koganty, B. M. Longnecker, T.-J. Yao, H. F. Oettgen, P. O. Livingston, Cancer Res. 1995, 55, 2783.
111. G. Ragupathi, S. F. Slovin, S. Adluri, D. Sames, I. J. Kim, H. Kim, M. Spassova, W. G. Bornmann, K. O. Lloyd, H. I. Scher, P. O. Livingston, S. J. Danishefsky, Angew. Chem. 1999, 111, 590; Angew. Chem. Int. Ed. 1999, 38, 563.
112. G. Ragupathi, S. F. Slovin, S. Adluri, D. Sames, I. J. Kim, H. Kim, M. Spassova, W. G. Bornmann, K. O. Lloyd, H. I. Scher, P. O. Livingston, S. J. Danishefsky, Angew. Chem. 1999, 111, 590; Angew. Chem. Int. Ed. 1999, 38, 563.
113. The vaccine conjugate was administered and used under an IND (investigational new drug) protocol with the Food and Drug Administration (USA) held by the Memorial Sloan-Kettering Cancer Center.
114. S. F. Slovin, G. Ragupathi, S. Adluri, G. Ungers, K. Terry, S. Kim, M. Spassova, W. G. Bornmann, M. Fazzari, L. Dantis, K. Olkiewicz, K. O. Lloyd, P. O. Livingston, S. J. Danishefsky, H. I. Scher, Proc. Natl. Acad. Sci. USA 1999, 96, 5710.
115. To date, we are in the position where we can synthesize fully deprotected allyl glycoside 40 on a gram scale with minimal complications.
116. E. Nudelman, S. B. Levery, T. Kaizu, S. Hakomori, J. Biol. Chem. 1986, 261, 11247.
117. a) T. Kaizu, S. B. Levery, E. Nudelman, R. E. Stenkamp, S. Hakomori, J. Biol. Chem. 1986, 261, 11254;
118. b) S. Y. Kim, M. Yuan, S. H. Itzkowitz, Q. Sun, T. Kaizu, A. Palekar, B. F. Trump, S.-I. Hakamori, Cancer Res. 1986, 46, 5985.
119. P. D. Jeffrey, J. Bajorath, C. Y. Chang, Y. Dale, I. Hellstrom, E. K. Hellstrom, S. Sheriff, Nat. Struct. Biol. 1995, 2, 466.
120. a) For a communication of parts of this work see: P. P. Deshpande, S. J. Danishefsky, Nature 1997, 387, 164;
121. b) another synthesis of nonconjugated KH-1 antigen was reported while our manuscript ([63]) was being reviewed: G. Hummel, R. R. Schmidt, Tetrahedron Lett. 1997, 38, 1173.
122. a) A.-C. Helland, M. Nilsson, T. Norberg, J. Carbohydr. Chem. 1992, 11, 77;
123. b) R. Windmüller, R. R. Schimidt, Tetrahedron Lett. 1994, 35, 7927.
124. P. P. Deshpande, H. M. Kim, A. Zatorski, T. K. Park, G. Ragupathi, P. O. Livingston, D. Live, S. J. Danishefsky, J. Am. Chem. Soc. 1998, 120, 1600.
125. P. H. Seeberger, M. Eckhardt, C. E. Gutteridge, S. J. Danishefsky, J. Am. Chem. Soc. 1997, 119, 10064.
126. G. Ragupathi, P. P. Deshpande, K. O. Lloyd, S. J. Danishefsky, P. O. Livingston, unpublished results.
127. a) O. Nilsson, J.-E. Mansson, T. Brezicka, J. Holmgren, L. Lindholm, S. Sorenson, F. Yngvason, L. Svennerholm, Glycoconjugate J. 1984, 1, 43;
128. b) F. T. Brezicka, S. Olling, O. Nilsson, J. Bergh, J. Holmgren, S. Sorenson, F. Yngvason, Cancer Res. 1989, 49, 1300.
129. a) O. Nilsson, T. F. Brezicka, J. Holmgren, S. Sorenson, L. Svennerholm, F. Yngvason, L. Lindholm, Cancer Res. 1986, 46, 1403;
130. b) A. J. Vangsted, H. Clausen, T. B. Kjeldsen, T. White, B. Sweeney, S. Hakomori, L. Drivsholm, J. Zeuthen, Cancer Res. 1991, 51, 2879.
131. S. Zhang, C. Cordon-Cardo, H. S. Zhang, V. E. Reutter, S. Adluri, W. B. Hamilton, K. O. Lloyd, P. O. Livingston, Int. J. Cancer 1997, 73, 42.
132. J. R. Allen, G. Ragupathi, P. O. Livingston, S. J. Danishefsky, J. Am. Chem. Soc. 1999, 121, 10875.
133. a) O. Kwon, S. J. Danishefsky, J. Am. Chem. Soc. 1998, 120, 1588;
134. b) S. Bhattacharya, S. J. Danishefsky, J. Org. Chem. 2000, 65, 144.
135. E. B. Rodriguez, R. V. Stick, Aust. J. Chem. 1990, 43, 665.
136. a) M. M. Sim, H. Kondo, C.-H. Wong, J. Am. Chem. Soc. 1993, 115, 2260;
137. b) M. D. Chappell, R. L. Halcomb. Tetrahedron 1997, 53, 11109.
138. J. A. Allen, J. G. Allen, X.-F. Zhang, L. J. Williams, A. Zatorski, unpublished results.
139. B. E. Anderson, M. Grove, L. E. Davis, US 5376531, 1994.
140. H. M. Kim, I. J. Kim, unpublished results.
141. I. Carlstedt, J. R. Davies, Biochem. Soc. Trans. 1997, 25, 214.
142. P. A. Poland, C. L. Kinlough, M. D. Rokaw, J. Magarian-Blander, O. J. Finn, R. P. Hughey, Glycoconjugate J. 1997, 14, 89.
143. a) G. F. Springer, Science 1984, 224, 1198;
144. b) B. J. Campbell, E. F. Finnie, E. F. Hounsell, J. M. Rhodes, J. Clin. Invest. 1995, 95, 571.
145. a) G. F. Springer, Clin. Rev. Oncogenesis 1995, 6, 57;
146. b) G. D. MacLean, M. A. Reddish, M. B. Bowen-Yacyshyn, S. Poppema, B. M. Longenecker, Cancer Invest. 1994, 12, 45;
147. c) H. J. Jennings, F. E. Ashton, A. Gamian, F. Michon in Towards Better Carbohydrate Vaccines (Eds.: R. Roy, R. Bell, G. Torrigiani), Wiley, London, 1987, pp. 11-17.
148. a) G. D. MacLean, M. A Reddish, R. R. Koganty, T. Wong, S. Gandhi, M. Smolenski, J. Samuel, J. M. Nabholtz, B. M. Longnecker, Cancer Immunol Immunother. 1993, 36, 215;
149. b) R. Schneerson, J. B. Robbinson, S. C. Szu, Y. Yang in Towards Better Carbohydrate Vaccines (Eds.: R. Roy, R. Bell, G. Torrigiani), Wiley, London, 1987, pp. 307-327.
150. For examples of previous Tn syntheses see: T. Tokoyuni, S. Hakomori, A. K. Singhal, Bioorg. Med. Chem. 1994, 11, 1119, and references therein. For examples of Tn glycopeptide clusters see: S. Bay, R. Lo-Man, E. Osinaga, H. Nakada, C. Leclerc, D. Cantacuzene, J. Pept. Res. 1997, 49, 620, and references therein.
151. For examples of previous Tn syntheses see: T. Tokoyuni, S. Hakomori, A. K. Singhal, Bioorg. Med. Chem. 1994, 11, 1119, and references therein. For examples of Tn glycopeptide clusters see: S. Bay, R. Lo-Man, E. Osinaga, H. Nakada, C. Leclerc, D. Cantacuzene, J. Pept. Res. 1997, 49, 620, and references therein.
152. For selected interesting examples of glycoprotein syntheses see: a) R. M. Bill, S. L. Flitsch, Chem. Biol. 1996, 3, 145;
153. b) K. Witte, P. Sears, K. Martin, C.-H. Wong, J. Am. Chem. Soc. 1997, 119, 2114;
154. c) T. Tsuda, S. Nithimura, Chem. Commun. 1996, 2779.
155. For other cassette related approaches, see: E. Meinjohanns, M. Meldal, H. Paulsen, A. Schleyer, K. Bock, J. Chem. Soc. Perkin. Trans. 1 1996, 985; N. Mathieux, H. Paulsen, M. Meldal, K. Bock, J. Chem. Soc. Perkin. Trans. 1 1997, 2359; Y. Nakahara, H. Iijima, T. Ogawa, Tetrahedron Lett. 1994, 35, 3321; B. Liebe, H. Kunz, Tetrahedron Lett. 1994, 35, 8777.
156. For other cassette related approaches, see: E. Meinjohanns, M. Meldal, H. Paulsen, A. Schleyer, K. Bock, J. Chem. Soc. Perkin. Trans. 1 1996, 985; N. Mathieux, H. Paulsen, M. Meldal, K. Bock, J. Chem. Soc. Perkin. Trans. 1 1997, 2359; Y. Nakahara, H. Iijima, T. Ogawa, Tetrahedron Lett. 1994, 35, 3321; B. Liebe, H. Kunz, Tetrahedron Lett. 1994, 35, 8777.
157. For other cassette related approaches, see: E. Meinjohanns, M. Meldal, H. Paulsen, A. Schleyer, K. Bock, J. Chem. Soc. Perkin. Trans. 1 1996, 985; N. Mathieux, H. Paulsen, M. Meldal, K. Bock, J. Chem. Soc. Perkin. Trans. 1 1997, 2359; Y. Nakahara, H. Iijima, T. Ogawa, Tetrahedron Lett. 1994, 35, 3321; B. Liebe, H. Kunz, Tetrahedron Lett. 1994, 35, 8777.
158. For other cassette related approaches, see: E. Meinjohanns, M. Meldal, H. Paulsen, A. Schleyer, K. Bock, J. Chem. Soc. Perkin. Trans. 1 1996, 985; N. Mathieux, H. Paulsen, M. Meldal, K. Bock, J. Chem. Soc. Perkin. Trans. 1 1997, 2359; Y. Nakahara, H. Iijima, T. Ogawa, Tetrahedron Lett. 1994, 35, 3321; B. Liebe, H. Kunz, Tetrahedron Lett. 1994, 35, 8777.
159. X. T. Chen, D. Sames, S. J. Danishefsky, J. Am. Chem. Soc. 1998, 120,
160. R. U. Lemieux, R. M. Ratcliffe, Can. J. Chem. 1979, 57, 1244.
161. S. D. Kuduk, J. B. Schwarz, X. T. Chen, P. W. Glunz, D. Sames, G. Ragupathi, P. O. Livingston, S. J. Danishefsky, J. Am. Chem. Soc. 1998, 120, 12474.
162. For reviews on the synthesis of α-O-linked serine or threonine glycopeptides see a) H. Kunz, Pure Appl. Chem. 1993, 65, 123;
163. b) H. Kunz, Adv. Carbohydr. Chem. Biochem. 1994, 50, 277.
164. H. R. Brugghe, Int. J. Peptide Protein Res. 1994, 43, 166.
165. T. Tokoyuni, S. Hakomori, A. K. Singhal, Bioorg. Med. Chem. 1994, 11, 1119.
166. T. Tokoyuni, B. Dean, S. Cai, D. Boivin, S. Hakomori, A. K. Singhal, J. Am. Chem. Soc. 1994, 116, 395.
167. a) L. A. Carpino, J. Am. Chem. Soc. 1993, 115, 4397;
168. b) L. A. Carpino, D. Ionescu, A. El-Faham, J. Org. Chem. 1996, 61, 2460.
169. Synthetic compound 100 was conjugated to KLH using m-maleimidobenzoyl-N-hydroxysuccinamide ester (MBS), a heterobifunctional reagent which cross-links thiol groups with amino groups.
170. Mono-and diclusters of the TF antigen have been reported: H. Kunz, S. Birnbach, P. Wering, Carbohydr. Res. 1990, 202, 207.
171. D. Sames, X. T. Chen, S. J. Danishefsky, Nature 1997, 389, 587.
172. J. B. Schwarz, S. D. Kuduk, X. T. Chen, D. Sames, P. W. Glunz, S. J. Danishefsky, J. Am. Chem. Soc. 1999, 121, 2662.
173. For previous syntheses of 2,6-STF see: a) H. Iijima, T. Ogawa, Carbohydr. Res. 1989, 186, 95;
174. b) D. Qiu, R. R. Koganty, Tetrahedron Lett. 1996, 37, 595;
175. c) D. Qui, R. R. Koganty, Tetrahedron Lett. 1997, 38, 961.
176. For previous syntheses of STn see: a) H. Kunz, B. Liebe, Helv. Chim. Acta. 1997, 80, 1473;
177. b) H. Kunz, B. Liebe, Angew. Chem. 1997, 109, 629; Angew. Chem. Int. Ed. Engl. 1997, 36, 618;
178. b) H. Kunz, B. Liebe, Angew. Chem. 1997, 109, 629; Angew. Chem. Int. Ed. Engl. 1997, 36, 618;
179. c) H. Iijima, T. Ogawa, Carbohyr. Res. 1988, 172, 183.
180. P. W. Glunz, S. Hintermann, J. B. Schwarz, S. D. Kuduk, X. T. Chen, L. J. Williams, D. Sames, S. J. Danishefsky, V. Kudryashov, K. O. Lloyd, J. Am. Chem. Soc. 1999, 121, 10636.
181. B. O. Fraser-Reid, U. E. Udodong, W. Zufan, H. Ottosson, R. Merritt, S. Rao, C. Roberts, R. Madsen, Synlett 1992, 927.
182. P. W. Glunz, unpublished results.
183. a) P. Konradsson, D. R. Mootoo, R. E. McDevitt, B. Fraser-Reid, J. Chem. Soc. Chem. Commun. 1990, 270;
184. b) P. Konradsson, U. E. Udodong, B. Fraser-Reid, Tetrahedron Lett. 1990, 31, 4313.
185. Conditions including pH10 aq. NaOH/MeOH, LiOH, LiOOH, and cat. NaOMe/MeOH failed to remove the three benzoates.
186. K. Kitamura, E. Stockert, P. Garin-Chesa, S. Welt, K. O. Lloyd, K. L. Armour, T. P. Wallace, W. J. Harris, F. J. Carr, L. J. Old, Proc. Natl. Acad. Sci. USA 1994, 91, 12957-12961.
187. D. Live, L. J. Williams, S. D. Kuduk, J. B. Schwarz, P. W. Glunz, X. T. Chen, D. Sames, R. A. Kumar, S. J. Danishefsky, Proc. Natl. Acad. Sci. USA 1999, 96, 3489.